## Karmele Valencia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3775831/publications.pdf

Version: 2024-02-01

567281 713466 24 914 15 21 citations h-index g-index papers 25 25 25 1689 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	miRNA cargo within exosomeâ€like vesicle transfer influences metastatic bone colonization. Molecular Oncology, 2014, 8, 689-703.	4.6	155
2	Inhibition of Collagen Receptor Discoidin Domain Receptor-1 (DDR1) Reduces Cell Survival, Homing, and Colonization in Lung Cancer Bone Metastasis. Clinical Cancer Research, 2012, 18, 969-980.	7.0	121
3	An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nature Communications, 2017, 8, 14294.	12.8	119
4	Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nature Cancer, 2020, 1, 75-85.	13.2	68
5	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Letters, 2022, 529, 70-84.	7.2	51
6	Receptor of Activated Protein C Promotes Metastasis and Correlates with Clinical Outcome in Lung Adenocarcinoma. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 96-105.	5.6	45
7	miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis. Bone, 2013, 52, 532-539.	2.9	45
8	Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis. Journal of Pathology, 2016, 239, 438-449.	4.5	42
9	Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. Cancers, 2021, 13, 3016.	3.7	38
10	A gene signature of bone metastatic colonization sensitizes for tumor-induced osteolysis and predicts survival in lung cancer. Oncogene, 2014, 33, 5090-5099.	5.9	35
11	Exosomes in Liquid Biopsy: The Nanometric World in the Pursuit of Precision Oncology. Cancers, 2021, 13, 2147.	3.7	35
12	The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas. Journal of Clinical Investigation, 2020, 130, 1879-1895.	8.2	29
13	RHOB influences lung adenocarcinoma metastasis and resistance in a hostâ€sensitive manner. Molecular Oncology, 2014, 8, 196-206.	4.6	27
14	Molecular biomarkers in early stage lung cancer. Translational Lung Cancer Research, 2021, 10, 1165-1185.	2.8	23
15	Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. Cancer Discovery, 2022, 12, 1356-1377.	9.4	22
16	Tumor–stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models. Clinical and Experimental Metastasis, 2011, 28, 779-791.	3.3	17
17	Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1. Scientific Reports, 2019, 9, 15400.	3.3	13
18	All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS. Molecular and Cellular Oncology, 2017, 4, e1314239.	0.7	10

#	Article	lF	CITATIONS
19	The Usefulness of Bone Biomarkers for Monitoring Treatment Disease: A Comparative Study in Osteolytic and Osteosclerotic Bone Metastasis Models. Translational Oncology, 2017, 10, 255-261.	3.7	10
20	Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	5
21	Microvesicles: Isolation, Characterization for In Vitro and In Vivo Procedures. Methods in Molecular Biology, 2016, 1372, 181-192.	0.9	4
22	Inhibition of discoidin domain receptor-1 (DDR1) impairs tumor-induced osteoclastogenesis preventing bone metastatic homing and colonization. Bone, 2011, 48, S48-S49.	2.9	0
23	Liver Kinase B1 (LKB1) Loss Has its p-ERKs: ERK Inactivation as a Vulnerability in NSCLC With LKB1 Mutations. Journal of Thoracic Oncology, 2020, 15, 311-313.	1.1	O
24	Abstract PO-089: Identification of a LAMC2-regulated network featuring targetable effectors for dual therapies in pancreatic cancer. , 2021, , .		0